TY - JOUR
T1 - Nephropathy induced by contrast media
T2 - Pathogenesis, risk factors and preventive strategies
AU - Goldenberg, Ilan
AU - Matetzky, Shlomi
PY - 2005/5/24
Y1 - 2005/5/24
N2 - With the increasing use of contrast media in diagnostic and interventional procedures, nephropathy induced by contrast media has become the third leading cause of hospital-acquired acute renal failure. It is also associated with a significant risk of morbidity and death. The current understanding of the pathogenesis indicates that contrast-medium nephropathy is caused by a combination of renal ischemia and direct toxic effects on renal tubular cells. Patients with pre-existing renal insufficiency, diabetes mellitus and congestive heart failure are at highest risk. Risk factors also include the type and amount of contrast medium administered. Therapeutic prevention strategies are being extensively investigated, but there is still no definitive answer. In this article, we review the current evidence on the causes, pathogenesis and clinical course of contrast-medium nephropathy as well as therapeutic approaches to its prevention evaluated in clinical trials.
AB - With the increasing use of contrast media in diagnostic and interventional procedures, nephropathy induced by contrast media has become the third leading cause of hospital-acquired acute renal failure. It is also associated with a significant risk of morbidity and death. The current understanding of the pathogenesis indicates that contrast-medium nephropathy is caused by a combination of renal ischemia and direct toxic effects on renal tubular cells. Patients with pre-existing renal insufficiency, diabetes mellitus and congestive heart failure are at highest risk. Risk factors also include the type and amount of contrast medium administered. Therapeutic prevention strategies are being extensively investigated, but there is still no definitive answer. In this article, we review the current evidence on the causes, pathogenesis and clinical course of contrast-medium nephropathy as well as therapeutic approaches to its prevention evaluated in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=20444410007&partnerID=8YFLogxK
U2 - 10.1503/cmaj.1040847
DO - 10.1503/cmaj.1040847
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 15911862
AN - SCOPUS:20444410007
VL - 172
SP - 1461
EP - 1471
JO - CMAJ
JF - CMAJ
SN - 0008-4409
IS - 11
ER -